NewAmsterdam Pharma 株価情報 (NASDAQ: NAMS)

最新ニュース NewAmsterdam Pharma (NASDAQ:NAMS) 株価情報

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

NamSys Inc

WIIM

MYGN

Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 revenue guidance below estimates.

ProAssurance shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is looking for FY2025 FFO of $0.90-$1.00 vs $0.97 analyst estimate..

News

Guidance

Summit Hotel Properties Sees FY2025 AFFO per common share $0.90-$1.00 vs $0.97 Est

PRIM

Primoris Services shares are trading higher following better-than-expected Q4 financial results.

The Cheesecake Factory Incorporated (the "Cheesecake Factory") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) today announced its intention to offer, subject to market and other conditions, $450,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Cheesecake Factory also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $67,500,000 principal amount of notes.
The notes will be senior, unsecured obligations of The Cheesecake Factory, will accrue interest payable semi-annually in arrears and will mature on March 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. The Cheesecake Factory will settle conversions in cash and, if applicable, shares of its common stock.

Offerings

CAKE

The Cheesecake Factory  Announced Its Intention To Offer $450M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

The 2026 outlook is driven by expected volume growth from increased production and recently completed projects, and the continued realization of acquisition-related synergies.

ONEOK Expects Greater Than 15% EPS Growth And Adjusted EBITDA Growth Approaching 10% In 2026 Vs. 2025 Guidance Midpoints

Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) reported quarterly earnings of $0.20 per share which met the analyst consensus estimate. This is a 9.09 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $172.93 million which beat the analyst consensus estimate of $172.08 million by 0.49 percent. This is a 2.54 percent decrease over sales of $177.44 million the same period last year.

Earnings

Earnings Beats

Summit Hotel Properties Q4 AFFO per common share $0.20, Inline, Sales $172.93M Beat $172.08M Estimate

Zoom Communications Sees FY26 Revenue $4.785B-$4.795B Vs $4.809B Estimate; Sees Adj. EPS $5.34-$5.37 Vs $5.36 Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) sees FY2025 sales of $302.000 million-$307.000 million vs $305.87 million analyst estimate.

HSTM

HealthStream Sees FY2025 Sales $302.000M-$307.000M vs $305.87M Est

SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) sees FY2025 sales of $193.500 million-$195.500 million vs $193.47 million analyst estimate.

SIBN

SI-BONE Sees FY2025 Sales $193.500M-$195.500M vs $193.47M Est

MAIA

MAIA Biotechnology Announces $1.43M Non-Brokered Private Placement Of 952,300 Shares At $1.50/Share

BOOM

DMC Global shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 revenue guidance above estimates.

Zoom Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) reported fourth-quarter financial results after the market close on Monday. Here&#8217;s a rundown of the report.
Q4 Earnings: Zoom reported fourth-quarter revenue of $1.18 billion, in line with <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>. The communications company reported fourth-quarter adjusted earnings of $1.41&nbsp;per share, beating analyst estimates of $1.30&nbsp;per share.
Zoom has now met or exceeded analyst estimates on the top and bottom lines in ten consecutive quarters, according to data from <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 3.3% on a year-over-year basis. Enterprise revenue was up&nbsp;5.9%&nbsp;year-over-year, while online revenue fell 0.4% year-over-year.&nbsp;Zoom noted online monthly average churn was down 20 basis points to&nbsp;2.8% in the quarter. Zoom&nbsp;ended the quarter&nbsp;with approximately 192,600&nbsp;enterprise customers. 
Net cash provided by operating activities was&nbsp;$424.6 million&nbsp;in the&nbsp;fourth quarter, up 20.9% year-over-year. Free cash flow came in at $416.2 million, up 25.1% year-over-year. Zoom ended the quarter with $7.8 billion in cash, cash equivalents and marketable securities.
&#8220;In FY25, Zoom AI Companion emerged as the driving force behind our transformation into an AI-first company, enabling our customers to discover enhanced productivity opportunities. As Zoom AI Companion becomes increasingly agentic, we look forward to continuing to help our customers fully realize the benefits of AI and discover what&#8217;s possible with AI agents,&#8221; said&nbsp;Eric Yuan, founder and CEO of Zoom.
See Also: <a href="https://www.benzinga.com/general/social-media/25/02/43917713/us-lawmakers-demand-eu-clarify-big-tech-regulations-that-may-target-american-companies">US Lawmakers Demand EU Clarify Big Tech Regulations That &#8216;May Target American Companies&#8217;</a>
Outlook:&nbsp;Zoom expects first-quarter revenue to be in the range of $1.162&nbsp;billion to $1.167 billion. The company sees first-quarter adjusted earnings of $1.29&nbsp;to $1.31 per share.
Zoom sees full-year 2026 revenue in the range of $7.785 billion to $4.795 billion. The company expects full-year adjusted earnings to be between $5.34 and $5.37 per share.
Zoom executives will further discuss the quarter on a call with investors and analysts set for 5 p.m. ET.
ZM Price Action: <a href="https://www.benzinga.com/quote/ZM" target="_blank" rel="noreferrer noopener">Zoom shares</a> were down 2.25% after hours, trading at $79.27 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43920295/palantir-extends-losses-microsoft-slides-whats-driving-markets-monday">Palantir Extends Losses, Microsoft Slides: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Photo: Courtesy of Zoom Communications.

Movers

Zoom Communications Q4 Earnings: EPS Beat, Revenue In Line As Company Continues Transformation Into 'AI-First Company'

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.13 by 23.08 percent. This is a 6.67 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $74.23 million which beat the analyst consensus estimate of $73.54 million by 0.94 percent. This is a 5.18 percent increase over sales of $70.58 million the same period last year.

HealthStream Q4 EPS $0.16 Beats $0.13 Estimate, Sales $74.23M Beat $73.54M Estimate

SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 59.26 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $49.00 million which beat the analyst consensus estimate of $47.89 million by 2.33 percent. This is a 26.10 percent increase over sales of $38.86 million the same period last year.

SI-BONE Q4 EPS $(0.11) Beats $(0.14) Estimate, Sales $49.00M Beat $47.89M Estimate

UCTT

Ultra Clean Holdings shares are trading lower after the company issued Q1 guidance below estimates.

The market is coming off a relatively slow week and heading into what looks to be an eventful one. Stocks showed strength throughout the week but sold off sharply on Friday following a weaker consumer confidence report and growing fears of an economic slowdown due to tariffs and DOGE.
The spotlight this week is on NVIDIA, with $NVDA set to report earnings Wednesday after the bell. Investors aren't just looking for strong numbers—they'll be laser-focused on the company's guidance and Jensen Huang's outlook. Back in January, the release of China's DeepSeek large language model triggered a tech sell-off, sending Nvidia down 17% in a single session. Since then, sentiment has stabilized, but questions remain about the long-term impact on AI chip demand. Expect heightened volatility around the report, with guidance likely driving the stock's next big move.
Economic data was light last week, aside from Friday's disappointing consumer confidence report. This week, the main event is Core PCE, the Fed's preferred inflation measure, dropping Thursday morning. While I don't anticipate a major market shake-up, inflation has shown a persistent upward trend in recent CPI and PPI readings. Any upside surprise could keep rate-cut expectations in check.
With inflation fears bubbling up again, bearish sentiment has been creeping back into the market. Still, the S&amp;P 500 is holding onto a 2.46% gain year-to-date. Meanwhile, the 10-year Treasury yield has continued its decline, down roughly 8% since mid-January. In my view, lower yields are a tailwind for equities and should help support further upside.
Volatility is likely to stick around, and I wouldn't rule out a short-term pullback of around 5%. That said, I see any significant dip as a buying opportunity rather than a cause for concern.
My advice? Focus on the positive and keep an optimistic outlook.
&#x2A;&#x2A;
Welcome to the WOLF Financial Newsletter.
Join over 17,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
Subscribe
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more Here.
Disclaimer: Wolf Financial does NOT offer financial advice. All content provided is strictly for informational purposes. Wolf Financial is not registered as an investment, legal, or tax advisor, nor as a broker/dealer. Please be aware that trading any stock or crypto-related asset carries inherent risks and may lead to substantial capital losses.

Earnings Misses

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Federal Reserve

Market-Moving Exclusives

Exclusives

Markets

NVDA

NVIDIA And Inflation Fears In This Week's Market Forecast

Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.29) by 155.17 percent. This is a 10.84 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $109.90 million which beat the analyst consensus estimate of $105.90 million by 3.78 percent. This is a 7.88 percent decrease over sales of $119.30 million the same period last year.

CNNE

Cannae Holdings Q4 GAAP EPS $(0.74) Misses $(0.29) Estimate, Sales $109.90M Beat $105.90M Estimate

Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) sees FY2025 sales of $235.000 million-$255.000 million vs $267.50 million analyst estimate.

ISPO

Inspirato Sees FY2025 Sales $235.000M-$255.000M vs $267.50M Est

Zoom Communications Sees Q1 2026 Revenue $1.162B-$1.167B Vs $1.175B; Sees Adj. EPS $1.29-$1.31 Vs $1.35 Estimate

Press Releases

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Legal

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Financing

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

Comments

NewAmsterdam Pharma

ニュース

最新ニュース NewAmsterdam Pharma (NASDAQ:NAMS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル